Subvisible particles, measuring roughly 10 µm in size, can cause a range of serious health issues, from clogging capillaries to sparking life-threatening immune reactions. In response, the FDA has set strict standards for injectable drug products: they must be virtually free of them. Manufacturers need powerful technology solutions capable of fully characterizing subvisible particles throughout the development cycle to ensure therapies are safe and effective prior to patient use. Yet legacy particle analysis methods fail to provide adequate protection, leaving invisible particles unchecked and patient safety in danger.
With Aura Systems, subvisible particle counting and identification is possible at the very beginning of your process, a big step forward in speeding up development and helping prevent expensive bottlenecks. Discover how the Aura family of particle analyzers can help you develop stable, pure and efficacious protein, cell, and gene therapies faster, while preventing problems before they become expensive bottlenecks:
Using backgrounded membrane imaging (BMI) and fluorescence membrane microscopy (FMM), Aura Systems uncover crucial subvisible particle data, including size, particle diameter, morphology, count, and distribution, which leads to more accurate results and better insight. Detect and characterize particles not measured by dynamic light scattering (DLS) or size exclusion chromatography (SEC) while preserving your sample.
You achieve high sensitivity because particles are imaged and identified through fluorescence methods without the interference of buffer or matrix and see more detail for better particle identification with high-resolution magnification.
Using backgrounded membrane imaging (BMI) and fluorescence membrane microscopy (FMM), Aura Systems uncover crucial subvisible particle data, including size, particle diameter, morphology, count, and distribution, which leads to more accurate results and better insight. Detect and characterize particles not measured by dynamic light scattering (DLS) or size exclusion chromatography (SEC) while preserving your sample.
You achieve high sensitivity because particles are imaged and identified through fluorescence methods without the interference of buffer or matrix and see more detail for better particle identification with high-resolution magnification.
Application Note: Rapidly Distinguish Protein from Non-Protein Particles in Biologic Formulations
Refractive index differences between protein aggregates in aqueous solutions (FI) and air (HORIZON®). The higher refractive index contrast with the HORIZON® system improves data accuracy, robustness, and sensitivity.
Sizing with the Aura system. (A) Calibration with ASTM Microscope Slide. Particle size verification with (B) 15 µm and (C) 5 µm polystyrene bead standards as shown in the captured images from the Aura Particle Vue software tooltip.
LOQ determination for the Dynabead detection assay. Dynabead counts were measured in serial dilutions of cells mixed with Dynabeads and graphed as the average number of beads/mL vs. dilution. Limit of quantification (LOQ ) shown below dotted line. R2= 0.98.
Subvisible particle counts (>2 µm/mL) for Sample A and Sample B treated with varying buffers.
Ultrafine particles and nanoparticles are both types of particles with dimensions on the nanometer scale, but they differ in their sources, properties, and applications. Ultrafine particles refer to particles with sizes typically ranging from 1 to 100 nanometers, generated from natural or anthropogenic sources such as combustion processes, industrial emissions, or atmospheric aerosols. Nanoparticles, on the other hand, encompass a broader range of particle sizes up to 1000 nanometers and can be engineered or synthesized for various applications, including drug delivery, imaging, diagnostics, and materials science. While both ultrafine particles and nanoparticles exhibit unique physicochemical properties due to their small size, nanoparticles are designed and manipulated to achieve specific functionalities or behaviors, whereas ultrafine particles may arise as byproducts of natural or human activities.
Subvisible particles, which include particles larger than 1 micron in size, can be measured using various analytical techniques to assess the quality and safety of pharmaceutical products. Common methods for measuring subvisible particles include:
These methods enable the detection, quantification, and characterization of subvisible particles in pharmaceutical formulations, ensuring compliance with regulatory standards and product specifications.
Particle size determination involves measuring the dimensions of particles in a sample, which can vary from nanometers to micrometers depending on the application and analytical technique. Common methods of determining particle size include:
These methods offer complementary approaches to characterizing particle size, allowing researchers to select the most suitable technique based on sample properties, size range, and measurement requirements.
Quantitative methods for determining particle size distribution involve measuring the frequency or proportion of particles within specific size ranges in a sample. Common quantitative methods include:
These quantitative methods offer precise and reliable approaches to characterizing particle size distribution, enabling researchers to assess the uniformity, stability, and performance of particulate samples in various applications
Particulate contaminants in pharmaceutical products can arise from various sources and may include foreign particles such as glass shards, metal fragments, fibers, or microbial contaminants. Common particulate contaminants encountered in pharmaceutical manufacturing include visible particles (>50 micrometers), subvisible particles (1-50 micrometers), and microbial particles (e.g., bacteria, fungi). These contaminants can originate from raw materials, packaging components, manufacturing equipment, or environmental sources. Particulate contamination poses risks to product quality, efficacy, and patient safety, necessitating rigorous quality control measures and analytical testing throughout the manufacturing process to detect and mitigate contamination issues.
Particle count testing in the pharmaceutical industry involves quantifying the number and size distribution of particles present in pharmaceutical formulations or manufacturing processes. This testing is critical for assessing product quality, ensuring compliance with regulatory standards, and identifying potential contamination issues. USP 788 has largely been accepted as the industry standard for particle count testing guidance. Common methods for particle count testing include light obscuration, microscopy particle counting, and dynamic image analysis. These techniques provide quantitative data on the concentration and size distribution of particles, enabling manufacturers to monitor and control particle levels within acceptable limits. The Aura family of instruments can identify, size and count microbial particles easily, accurately and quickly. Particle count testing is particularly important for injectable drug products, where excessive particulate matter can pose risks to patient safety, such as embolism or injection site reactions.
Controlling contamination requires implementing comprehensive quality control measures and adhering to good manufacturing practices (GMP). Key strategies for contamination control include:
All cells share certain fundamental characteristics, some of these including:
These fundamental characteristics are essential for the survival and function of all cells, regardless of their type or function within an organism.
The polydispersity index (PDI) is a measure of the width of the particle size distribution in a sample. A low PDI indicates a more uniform particle size, which is often desired for stability and performance in pharmaceutical formulations.